PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million [Yahoo! Finance]
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: Yahoo! Finance
MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results Preliminary Q1 2025 Q1 2024 Revenue $36.9 million $38.8 million Instrument revenue $10.8 million $19.0 million Consumable revenue $20.1 million $16.0 million Service and other revenue $6.0 million $3.8 million Revio systems Vega systems Annualized Revio pull-through per system ~$236,000 ~$254,000 Cash, cash equivalents, and investments $343.1 million $561.9 million Our preliminary revenue for the first quarter met our expectations despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds affecting the industry. Vega system orders accelerated in the first quarter as compared to the fourth quarter of 2024 as the combination of system capability and its attractive price point enabled purchases fr
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Pacific Biosciences: Longer Reads, But Shorter Patience (Downgrade) [Seeking Alpha]Seeking Alpha
- Pacific Biosciences of California (NASDAQ:PACB) had its price target raised by analysts at Barclays PLC from $1.50 to $2.00. They now have an "equal weight" rating on the stock.MarketBeat
- Why PacBio (PACB) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
- PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- PacBio to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
PACB
Earnings
- 11/5/25 - Beat
PACB
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/5/25 - Form 8-K
- PACB's page on the SEC website